Porphyrin-Based Tumor-Targeting Theranostic Agent: Gd-TDAP

The aim of this work was to evaluate a tumor-targeting porphyrin-based gadolinium complex (Gd-TDAP) for use as an MR/optical imaging agent and potential therapeutic agent. Gd-TDAP had higher longitudinal relaxivity (11.8 mM–1 s–1) than a commercial MRI contrast agent (Omniscan; 3.7 mM–1 s–1) in HSA...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ACS medicinal chemistry letters 2021-09, Vol.12 (9), p.1459-1463
Hauptverfasser: Kim, Soyeon, Yang, Ji-ung, Ahn, Jae Hun, Ko, In Ok, Kim, Jung Young, Lee, Yong Jin, Park, Ji-Ae
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The aim of this work was to evaluate a tumor-targeting porphyrin-based gadolinium complex (Gd-TDAP) for use as an MR/optical imaging agent and potential therapeutic agent. Gd-TDAP had higher longitudinal relaxivity (11.8 mM–1 s–1) than a commercial MRI contrast agent (Omniscan; 3.7 mM–1 s–1) in HSA solution (0.67 mM) at 3 T. The tumor-targeting characteristics were confirmed by T1-weighted MR imaging and optical imaging using an orthotopic brain tumor mouse model, which showed 1.3-fold higher uptake in tumor compared to normal brain tissues. The cell fraction data using U87MG glioblastoma cells indicated the potential for gadolinium neutron capture therapy (Gd-NCT), which requires gadolinium to be inside the cell nucleus. In addition, porphyrin derivatives can be used for photodynamic therapy (PDT), and the results demonstrated that Gd-TDAP has great potential not only as a bimodal imaging agent but also for treatment.
ISSN:1948-5875
1948-5875
DOI:10.1021/acsmedchemlett.1c00283